-+ 0.00%
-+ 0.00%
-+ 0.00%

Canaccord Genuity Maintains Buy on TransMedics Group, Lowers Price Target to $124

Benzinga·05/06/2026 23:00:38
Listen to the news
Canaccord Genuity analyst William Plovanic maintains TransMedics Group (NASDAQ:TMDX) with a Buy and lowers the price target from $152 to $124.